LPS pretreatment protects from hepatic ischemia/reperfusion

Area of Science:

• Immunology
• Hepatology
• Surgical Research

Background:

• Lipopolysaccharide (LPS) administration can induce tolerance to subsequent endotoxin challenge.
• Hepatic ischemia/reperfusion (I/R) injury is known to be dependent on tumor necrosis factor-alpha (TNF).
• The protective effect of LPS pretreatment against hepatic I/R injury was investigated.

Purpose of the Study:

• To determine if sublethal lipopolysaccharide (LPS) pretreatment protects against hepatic ischemia/reperfusion (I/R) injury.
• To analyze the effect of LPS pretreatment on tumor necrosis factor-alpha (TNF) release during hepatic I/R.

Main Methods:

• Five groups of rats were studied: LPS-I/R, VEH-I/R, LPS-LPS, VEH-LPS, and SHAM.
• LPS or vehicle was administered intravenously 24 hours prior to either I/R or sham laparotomy.
• Plasma TNF levels were measured at peak release (30-150 minutes post-reperfusion).

Main Results:

• Hepatic I/R in LPS-pretreated rats (LPS-I/R) showed significantly higher TNF levels compared to vehicle-pretreated rats (VEH-I/R) (P = 0.014).
• While LPS pretreatment reduced TNF release in response to a second LPS dose (VEH-LPS vs LPS-LPS), it increased TNF release following hepatic I/R.
• Peak plasma TNF levels varied significantly across groups, with VEH-LPS showing the highest levels.

Conclusions:

• Lipopolysaccharide (LPS) pretreatment does not confer protection against hepatic ischemia/reperfusion (I/R) injury.
• LPS pretreatment paradoxically enhances TNF release in the context of hepatic I/R.
• The findings challenge the hypothesis that LPS-induced tolerance protects against I/R-mediated organ damage.